Skip to main content
Premium Trial:

Request an Annual Quote

Pfizer Grabs Pharmacia, Creates $7 Billion R&D Powerhouse

NEW YORK, July 15-Pfizer's acquisition of Pharmacia, announced today, will create a drug research powerhouse with a total R&D budget projected to top $7 billion.


This research jackpot would dwarf the budgets of other big spenders in the pharmaceutical arena and make Pfizer the undisputed leader in drug development spending.


In 2001, Pfizer spent $4.8 billion on research, and Pharmacia doled out $2.3 billion.


The nearest rival, GlaxoSmithKline, spent 2.5 billion pounds (nearly $4 billion U.S.) on R&D in 2000.


In the acquisition, Pfizer will assume control of a combined R&D pipeline of nearly 120 drugs currently in development.


Pfizer will also take charge of a number of recent collaborations that Pharmacia has struck with companies in the genomics and proteomics sectors.


In the last year, Pharmacia arranged an antisense inhibitor gene validation deal with Isis, a gene library agreement with Galapagos Genomics for target identification and validation, and a pharmacogenomics collaboration with DeCode Genetics. It also has a structural proteomics collaboration with Syrrx, which the biotech company claims is the pharmaceutical industry's first large-scale, multi-family research project in structural proteomics.


Pfizer, for its part, has recently struck an expanded toxicogenomics partnership with Gene Logic, arranged licenses for Gene-IT's sequence-comparing software and for Lion's ADME simulation platform, and launched a deal with Athersys to create human cell lines that express drug targets.


Pfizer will acquire Pharmacia through a stock-for-stock transaction valued at $60 billion. The company will exchange 1.4 shares of Pfizer stock for each share of Pharmacia stock, a premium of roughly 35 percent over Pharmacia's Friday closing price. Pharmacia will continue with its spin-off of Monsanto.

The Scan

Study Examines Insights Gained by Adjunct Trio RNA Sequencing in Complex Pediatric Disease Cases

Researchers in AJHG explore the diagnostic utility of adding parent-child RNA-seq to genome sequencing in dozens of families with complex, undiagnosed genetic disease.

Clinical Genomic Lab Survey Looks at Workforce Needs

Investigators use a survey approach in Genetics in Medicine Open to assess technologist applications, retention, and workforce gaps at molecular genetics and clinical cytogenetics labs in the US.

Study Considers Gene Regulatory Features Available by Sequence-Based Modeling

Investigators in Genome Biology set sequence-based models against observational and perturbation assay data, finding distal enhancer models lag behind promoter predictions.

Genetic Testing Approach Explores Origins of Blastocyst Aneuploidy

Investigators in AJHG distinguish between aneuploidy events related to meiotic missegregation in haploid cells and those involving post-zygotic mitotic errors and mosaicism.